The recent price drop in Hims & Hers Health (HIMS), due to news about TrumpRx, presents a significant buying opportunity. The market is incorrectly valuing HIMS as a simple digital pharmacy, failing to recognize its superior integrated business model. HIMS bundles telehealth doctor visits with customized subscription medications, creating a strong competitive advantage and high customer switching costs. This model positions HIMS to disrupt not only traditional pharmacies like CVS but also local doctor's offices. Investors with a long-term outlook should consider this dip an attractive entry point, as the stock is viewed as having substantial upside potential.

Hims & Hers Health, Inc. (HIMS)

• The stock was down around -4% to -5% on the news of a new government-run online pharmacy called TrumpRx. The speaker believes this price movement is based on a fundamental misunderstanding of the HIMS business model by the market.
• The market incorrectly views HIMS as just another digital pharmacy, lumping it in with competitors like Amazon Pharmacy, Mark Cuban's Cost Plus Drugs, and the newly announced TrumpRx.
• The speaker argues that the core competitive advantage of HIMS is not just being an online pharmacy, but its unique, integrated business model.
  • Bundled Service: HIMS combines an e-doctor (telehealth consultation) with an e-pharmacy into a single monthly subscription price, similar to a Netflix subscription. This is a key differentiator from platforms like TrumpRx, where a user would still need to get a separate prescription from their own doctor.
  • No Insurance Model: HIMS operates outside the traditional insurance system, which simplifies the process and can be cheaper than the out-of-pocket costs many Americans pay even with insurance. The speaker notes the average American pays $2,400 a year in out-of-pocket costs, which is the market HIMS targets.
  • Marketing Prowess: The company is described as a "well-oiled machine" when it comes to marketing and building its brand.
  • Customization & Compounding: HIMS has the ability to create customized, compounded medications that combine treatments for multiple issues (e.g., hair loss and ED) into a single pill. This increases patient adherence and creates high switching costs, as customers are unlikely to find the same custom pill elsewhere.
  • Vertical Integration: The company is vertically integrated with automated warehouses and even produces its own ingredients, like peptides for weight loss drugs.
  • AI-Ready: The platform uses recommender systems and is built to leverage AI to help its network of providers (mostly nurse practitioners) make faster, more efficient decisions.
  • Customer-Centric: If a provider determines a patient doesn't qualify for a medication, the patient does not pay. This is contrasted with a traditional doctor's visit where you pay for the consultation regardless of the outcome.

Takeaways

• The speaker is extremely bullish on HIMS and views the recent price drop as a "buy the dip opportunity."
• The investment thesis is that HIMS is a disruptor of both traditional pharmacies (like CVS and Walgreens) and local "mom-and-pop" doctor offices, not just other online pharmacies.
• Investors should look beyond the simple "digital pharmacy" label and analyze the company's integrated subscription model, which bundles doctor access with customized medication, creating a strong competitive moat.
• The speaker has been covering the stock since it was $5 and is "not a seller of this stock anytime soon," believing it is going "way higher."

Pfizer (PFE)

• Pfizer is reportedly the company running or exclusively involved with the new TrumpRx initiative.
• On the day of the announcement, PFE stock was up 7%, in sharp contrast to the negative reaction in HIMS stock.
• This movement suggests the market views Pfizer's involvement in a government-backed, direct-to-consumer platform as a positive catalyst for the company.

Takeaways

• The positive stock reaction indicates that the market sees value in established pharmaceutical companies partnering with large-scale digital distribution platforms.
• This event highlights how different business models within the pharmaceutical and health sectors can be perceived by investors, with Pfizer being rewarded for a distribution partnership while HIMS was (wrongly, in the speaker's view) punished as a competitor.

Investment Theme: Digital Pharmacies & Telehealth

• The podcast highlights a major theme: the market's confusion in differentiating between various business models in the digital health space.
• A distinction is made between:
  • Pure Digital Pharmacies: Platforms like TrumpRx and Cost Plus Drugs that focus on fulfilling prescriptions online at a lower cost. They still require the user to have a prescription from an external doctor.
  • Coupon Sites: GoodRx (GDRX) is mentioned as a coupon website that is sometimes confused with HIMS but serves a different purpose.
  • Integrated Telehealth Platforms: HIMS is presented as the prime example, bundling the doctor consultation, prescription, and medication into one vertically integrated service.
• The speaker argues that traditional brick-and-mortar pharmacies like CVS and Walgreens are struggling as consumers increasingly move to buy medications online.

Takeaways

• When evaluating investments in the digital health sector, it is crucial to look beyond the surface-level description and understand the specific business model.
• The speaker believes the greatest value lies in integrated platforms like HIMS that solve multiple customer pain points (doctor access, cost, convenience) and create high switching costs through customization.
• The emergence of new platforms like TrumpRx creates volatility and potential mispricing in related stocks, which could present opportunities for investors who have "done their homework."